N. Harris, E. Jaffe, J. Diebold, G. Flandrin, H. Muller-hermelink et al., The World Health Organization Classification of Neoplasms of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting ??? Airlie House, Virginia, November, 1997, The Hematology Journal, vol.1, issue.1, pp.53-66, 1997.
DOI : 10.1038/sj.thj.6200013

A. Herrmann, E. Hoster, T. Zwingers, G. Brittinger, M. Engelhard et al., Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.4, pp.511-519, 2009.
DOI : 10.1200/JCO.2008.16.8435

M. Bernard, R. Gressin, F. Lefrere, B. Drenou, B. Branger et al., Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype, Leukemia, vol.15, issue.11, pp.1785-91, 2001.
DOI : 10.1038/sj.leu.2402272

P. Meusers, M. Engelhard, H. Bartels, T. Binder, H. Fulle et al., Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis, Hematological Oncology, vol.48, issue.5, pp.365-80, 1989.
DOI : 10.1002/hon.2900070505

E. Zucca, E. Roggero, G. Pinotti, E. Pedrinis, C. Cappella et al., Patterns of survival in mantle cell lymphoma, Annals of Oncology, vol.6, issue.3, pp.257-62, 1995.
DOI : 10.1093/oxfordjournals.annonc.a059155

A. Majlis, W. Pugh, M. Rodriguez, W. Benedict, and F. Cabanillas, Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants., Journal of Clinical Oncology, vol.15, issue.4, pp.1664-71, 1997.
DOI : 10.1200/JCO.1997.15.4.1664

W. Hiddemann, M. Unterhalt, R. Herrmann, H. Woltjen, E. Kreuser et al., Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group., Journal of Clinical Oncology, vol.16, issue.5, pp.1922-1952, 1998.
DOI : 10.1200/JCO.1998.16.5.1922

F. Lefrere, D. A. Levy, V. Delarue, R. Varet, B. et al., Sequential chemotherapy regimens followed by highdose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study, Haematologica, vol.89, issue.10, pp.1275-1281, 2004.

I. Khouri, J. Romaguera, H. Kantarjian, J. Palmer, W. Pugh et al., Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma., Journal of Clinical Oncology, vol.16, issue.12, pp.3803-3812, 1998.
DOI : 10.1200/JCO.1998.16.12.3803

F. Lefrere, A. Delmer, F. Suzan, V. Levy, C. Belanger et al., Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study, Leukemia, vol.16, issue.4, pp.587-93, 2002.
DOI : 10.1038/sj.leu.2402406

N. Milpied, F. Gaillard, P. Moreau, B. Mahe, J. Souchet et al., High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience, Bone Marrow Transplantation, vol.22, issue.7, pp.645-50, 1998.
DOI : 10.1038/sj.bmt.1701400

A. Freedman, D. Neuberg, J. Gribben, P. Mauch, R. Soiffer et al., High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission., Journal of Clinical Oncology, vol.16, issue.1, pp.13-21, 1998.
DOI : 10.1200/JCO.1998.16.1.13

N. Andersen, L. Pedersen, E. Elonen, A. Johnson, A. Kolstad et al., Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant, European Journal of Haematology, vol.96, issue.2, pp.73-80, 2003.
DOI : 10.1016/S1535-6108(03)00028-X

E. Vandenberghe, C. Ruiz-de-elvira, F. Loberiza, E. Conde, A. Lopez-guillermo et al., Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries, British Journal of Haematology, vol.6, issue.5
DOI : 10.1038/sj.bmt.1701400

J. Mangel, H. Leitch, J. Connors, R. Buckstein, K. Imrie et al., Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantlecell lymphoma: a matched pair analysis

M. Dreyling, G. Lenz, E. Hoster, A. Van-hoof, C. Gisselbrecht et al., Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network, Blood, vol.105, issue.7, pp.2677-84, 2005.
DOI : 10.1182/blood-2004-10-3883

C. Geisler, A. Kolstad, A. Laurell, N. Andersen, L. Pedersen et al., Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, vol.112, issue.7, pp.2687-93, 2008.
DOI : 10.1182/blood-2008-03-147025

R. Gressin, E. Legouffe, D. Leroux, M. Jacob, P. Swiercz et al., Treatment of mantle-cell lymphomas with the VAD +/chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation, Annals of Oncology, vol.8, issue.1+, pp.103-109, 1997.
DOI : 10.1023/A:1008278522789

E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht, A. Van-hoof et al., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, issue.2, pp.558-65, 2008.
DOI : 10.1182/blood-2007-06-095331

B. Cheson, S. Horning, B. Coiffier, M. Shipp, R. Fisher et al., Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, Journal of Clinical Oncology, vol.17, issue.4, p.1244, 1999.
DOI : 10.1200/JCO.1999.17.4.1244

B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht et al., Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-86, 2007.
DOI : 10.1200/JCO.2006.09.2403

G. Lenz, M. Dreyling, E. Hoster, B. Wormann, U. Duhrsen et al., Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG), Journal of Clinical Oncology, vol.23, issue.9, pp.1984-92, 2005.
DOI : 10.1200/JCO.2005.08.133

O. Howard, J. Gribben, D. Neuberg, M. Grossbard, C. Poor et al., Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival, Journal of Clinical Oncology, vol.20, issue.5, pp.1288-94, 2002.
DOI : 10.1200/JCO.2002.20.5.1288

J. Romaguera, L. Fayad, M. Rodriguez, K. Broglio, F. Hagemeister et al., High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine, Journal of Clinical Oncology, vol.23, issue.28, pp.7013-7036, 2005.
DOI : 10.1200/JCO.2005.01.1825

S. De-guibert, A. Jaccard, M. Bernard, P. Turlure, D. Bordessoule et al., Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma, Haematologica, vol.91, issue.3, pp.425-431, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00452943

A. Gianni, M. Magni, M. Martelli, D. Nicola, M. Carlo-stella et al., Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, vol.102, issue.2, pp.749-55, 2003.
DOI : 10.1182/blood-2002-08-2476

M. Rummel, S. Al-batran, S. Kim, M. Welslau, R. Hecker et al., Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.23, issue.15, pp.3383-3392, 2005.
DOI : 10.1200/JCO.2005.08.100

M. Rummel, N. Niederle, G. Maschmayer, A. Banat, U. Von-grunhagen et al., Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Blood, vol.114, p.168, 2009.

C. Tam and I. Khouri, Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma, Leukemia & Lymphoma, vol.24, issue.8, pp.1-10, 2009.
DOI : 10.1056/NEJMra0708875

P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba et al., Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome, Haematologica, vol.92, issue.1
DOI : 10.3324/haematol.10608

S. Murali, E. Winton, E. Waller, L. Heffner, S. Lonial et al., Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma, Bone Marrow Transplantation, vol.102, issue.8, pp.529-563, 2008.
DOI : 10.1038/bmt.2008.201

N. Andersen, L. Pedersen, A. Laurell, E. Elonen, A. Kolstad et al., Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.26, pp.4365-70, 2009.
DOI : 10.1200/JCO.2008.21.3116

W. Klapper, E. Hoster, O. Determann, I. Oschlies, J. Van-der-laak et al., Ki- 67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network, J Hematop, 2009.

O. Determann, E. Hoster, G. Ott, W. Bernd, H. Loddenkemper et al., Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group, Blood, vol.111, issue.4, pp.2385-2392, 2008.
DOI : 10.1182/blood-2007-10-117010

I. Khouri, M. Lee, R. Saliba, G. Jun, L. Fayad et al., Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma, Journal of Clinical Oncology, vol.21, issue.23
DOI : 10.1200/JCO.2003.05.501

M. Maris, B. Sandmaier, B. Storer, C. T. Stuart, M. Maziarz et al., Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma, Blood, vol.104, issue.12, pp.3535-3577, 2004.
DOI : 10.1182/blood-2004-06-2275

A. Ganti, P. Bierman, J. Lynch, R. Bociek, J. Vose et al., Hematopoietic stem cell transplantation in mantle cell lymphoma, Annals of Oncology, vol.16, issue.4, pp.618-642, 2005.
DOI : 10.1093/annonc/mdi107

M. Coleman, P. Martin, J. Ruan, R. Furman, R. Niesvizky et al., Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma, Leukemia & Lymphoma, vol.62, issue.3, pp.447-50, 2008.
DOI : 10.1182/blood-2005-04-1422